Industry Trends

A breakthrough for biomarker-altered breast cancer—but broader challenges remain.

New cardiovascular indication builds on treatment’s fast-growing legacy.

Launch campaign ramped up for disease-modifying drug that targets rare and fatal form of hypertension.

The author discusses how to calm the nerves of workers during periods of uncertainty.

Abrams discusses how both new pharma and big pharma are reacting to each other and the current market.

Webinar Date/Time: Thu, Sep 12, 2024 11:00 AM EDT

Velys recently received 510(k) clearance from the FDA for planning and instrumenting spinal fusion procedures across the cervical, thoracolumbar, and sacroiliac spine.

An unexpected consequence of the COVID 19 pandemic has been a loss in trust of vaccines. Over the past three flu seasons, there has been a drop in vaccination rates that is alarming experts. Dr. Gregg Sylvester, chief health officer at CSL Seqirus, spoke with Pharmaceutical Executive about the causes of the decline and how important it is to get the rates back to normal.

Biocon Biologic’s chief commercial officer of advanced markets discusses the current market and potential trends for biosimilars.

The deals leader at EY Global Life Sciences discusses how the first half of 2024 fared compared to 2023’s strong ending.

Webinar Date/Time: Wed, Aug 28, 2024 11:00 AM EDT

Webinar Date/Time: Thu, Aug 8, 2024 1:00 PM EDT

Advancements in periodontal disease could make way for expansions in the dental space and other medical fields.

JAMA study aims to discover how weight loss differs between patients receiving tirzepatide compared with semaglutide among a clinical population of overweight of obese adults.

A Harvard Business School Healthcare Alumni Association Q&A with Penn Center for Innovation’s Michael D. Moisel, MS, MBA.

A Q&A with Russell Reynolds’ Global Lead of CEO & Executive Transition Practice, Ty Wiggins, PhD.

Veeva’s vice president of global business consulting discusses recent trends in HCP access and how the pharma industry is reacting.

Q&A with Evaluate’s Paul Verdin digs deeper into the data-backed drivers likely to sway the future growth and jockeying of biopharma’s top players.

A Q&A with Korn Ferry’s co-managing director of the Global Education Practice, Kenneth L. Kring.

Highlighted by notable company and product maneuvering at the top and the continued dramatic growth of therapeutic settings such as GLP-1s, Pharm Exec’s latest listing of the top global biopharma sales producers is proof-positive of an industry in transition.

How pharma and biotech leaders can navigate today’s challenging landscape—focusing on revamped approaches in business operations, talent strategy and development, and more to meet the evolving demands.

What pharma needs to do to keep up with the rise in value-based care.

A Q&A with Egon Zehnder’s Sergio Della Zassa about what biopharma executives and search firms are looking for in terms of table stakes skill sets and “unicorn” experiences from top talent in the field.

A Q&A with Professor Frances Frei of the Harvard Business School, who discusses how leaders create the conditions for organizations and individuals to thrive by designing for excellence in operations, strategy, and culture.

A Harvard Business School Healthcare Alumni Association Q&A with Dorie Clark, Instructor of Executive Education at the Columbia Business School.

Partnership expected to utilize Walgreens’ pharmacies as recruitment and trial sites for a clinical study regarding obesity, weight issues, and type 2 diabetes, mainly in historically underrepresented groups.

A Harvard Business School Healthcare Alumni Association Q&A with Matt Wolf, president of Biopharma Services at Cencora.

Healthcare customers and patients are facing more avenues to receive misinformation about drugs than ever before.

Webinar Date/Time: Thursday, May 23, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

A Harvard Business School Healthcare Alumni Association Q&A with Louis Kassa, CEO of the Pennsylvania Biotechnology Center.